General Atlantic Discloses 11.5% Stake in Seaport Therapeutics Following IPO Participation

summarizeSummary

General Atlantic, L.P. and its affiliates have disclosed an 11.5% beneficial ownership stake in Seaport Therapeutics, Inc., stemming from the conversion of preferred stock and a $49.5 million purchase in the company's recent initial public offering.

check_boxKey Events

• New Major Shareholder

  General Atlantic, L.P. and its affiliates now beneficially own 6,101,582 shares, representing an 11.5% stake in Seaport Therapeutics.

• IPO Participation

  The General Atlantic group purchased 2,750,000 shares for $49.5 million at $18.00 per share during the company's initial public offering on May 4, 2026.

• Preferred Stock Conversion

  An additional 3,351,582 common shares were acquired through the automatic conversion of Series B convertible preferred stock upon the IPO's closing.

• Lock-Up Agreement

  General Atlantic has entered into a 180-day lock-up agreement, restricting sales of their shares until November 2026, aligning their interests with long-term company performance.

auto_awesomeAnalysis

This Schedule 13D filing reveals that General Atlantic, a significant institutional investor, has become a major shareholder in Seaport Therapeutics following its IPO. The acquisition of an 11.5% stake, including a substantial $49.5 million investment in the IPO, represents a strong vote of confidence in the newly public company. This strategic investment by a prominent firm could attract further institutional interest and provide stability for the stock, especially as it trades near its 52-week low.